Gut Health Solutions

The gut is fundamental to well-being, yet in a large-scale multinational study, it was found that more than 40% of people worldwide have digestive issue which affect quality of life and health-care utilization.¹ The demand for effective, reliable, and accessible solutions to support gut health among consumers is growing. 

Bayer’s Consumer Health Division offers a portfolio of trusted digestive health self-care solutions, ranging from globally recognized mega brands to locally relevant products, our local pearls, which are brands available only in specific markets. These products include leading efficacious formulations for heartburn and constipation, herbal formulations that have been researched and tested over a 60-year history, probiotics and digestive enzymes to address these unmet needs:

Backed by over 20 scientific studies, Iberogast® is one of the most thoroughly documented plant-based medicines for gastrointestinal disorders. The efficacy of Iberogast’s unique blend is supported by several medical guidelines used by doctors treating functional dyspepsia.² It acts on different parts of the gut due to its combination of hundreds of ingredients from a variety of herbal extracts that act synergistically.  A recent publication review offers a comprehensive summary of the evidence supporting Iberogast’s herbal formulation, highlighting its efficacy in digestive health.

Iberoflora® contains Lactobacillus rhamnosus LGG®, the world’s most studied probiotic strain, with strong evidence supporting its use in various gastrointestinal disorders in children. For adults, Iberoflora® offers three powerful probiotics and maltodextrin, all in a convenient capsule that fits seamlessly into busy lives.

MiraLAX® is the #1 doctor-recommended OTC brand in the United States for effective relief of occasional constipation. It works naturally with the water in your body to unblock your system without harsh side effects.

Alka-Seltzer® products offer fast relief from a variety of symptoms, including occasional heartburn, sour stomach, upset stomach associated with heartburn and acid indigestion, and pain.

Rennie® provides a fast-acting, effective remedy for heartburn and indigestion. Antacids like Rennie® neutralize excess stomach acid, helping to relieve acid reflux.

For over 40 years, Talcid® has helped people improve digestive health with safe and effective solutions for heartburn relief. In China, Talcid has expanded into the areas of indigestion and constipation relief.

First precision health tool to offer patients with IBS a novel, holistic approach. The app integrates multidisciplinary approaches such as cognitive behavior therapy (CBT) and dietary recommendations for treating IBS symptoms such as abdominal pain combined with irregular bowel movements.

Find out more about other digestive health brands such as Citrosodina, Dicoflor, Geffer, Lefax, Phillips, and explore our trusted self-care solutions here.

We understand that digestive problems can interfere with daily life and compromise overall health. Bayer continues to leverage science and innovation to ensure these disruptions do not hold consumers back, empowering them with evidence-based products that support healthy digestion and gut balance and relieve symptoms. Our commitment goes beyond symptom relief, we are actively advancing research into the gut-brain microbiome connection, driving forward new solutions that improve health outcomes.

This site is intended for an international audience. Not all products discussed may be available in your country. Local prescribing information and approved indications may vary.

¹ Sperber, Ami D. et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, Volume 160, Issue 1, 99 - 114.e3

² Global Rome guideline: Stanghellini et al. Gastroenterology 2016; 150 (6) 2. German S1 Guideline: Storr M et al. Z Gastroenterol 2025; 63: 403–422 . 3. Mexican Consensus: Carmona-Sánchez, R et al. Revista de gastroenterologia de Mexico vol. 82,4 (2017): 309-327